DUBLIN--(BUSINESS WIRE)--The "Latin America Drug Discovery Market 2019-2027" report has been added to ResearchAndMarkets.com's offering.
Market Outlook
According to this anaylysis, the Latin America drug discovery market is anticipated to register a CAGR of 7.65% for the forecasted period of 2019-2027.
The gradual rise in healthcare expenses has been helping pharmaceutical technology advancement and driving the drug discovery market in Latin America. For instance, there has been an increase in the usage of advanced technologies such as high throughput screening (HTS), spectroscopy, combinational chemistry, and bioinformatics for better drug identification.
Many pharmaceutical companies in Mexico have started shifting to personalized medicine to address the high mortality rate of cancer in the country. This approach is anticipated to contribute to the drug discovery process and create significant growth opportunities for the market. Academic communities have also started using HTS procedures to find potential drugs by collaborating with the government.
Due to the less investment, time, and risk, drug discovery is expected to be practiced largely in small niche biopharmaceutical companies. A large portion of the population in need of targeted drug delivery has been stimulating the government and local pharmaceutical labs to take up the initiative. It is predicted that the collaboration with contract development and manufacturing organizations would reduce the time and cost for big pharmaceutical companies to increase the market and further boost the growth of the drug discovery market.
Key Topics Covered:
1. Latin America Drug Discovery Market - Summary
2. Industry Outlook
2.1. Market Definition
2.2. Porter's Five Forces Model
2.2.1. Threats of New Entrants
2.2.2. Threat of Substitute Products
2.2.3. Bargaining Power of Buyers
2.2.4. Bargaining Power of Suppliers
2.2.5. Competitive Rivalry
2.3. Pestle Outlook
2.4. Value Chain Outlook
2.5. Market Attractiveness Index
2.6. Key Insight
2.7. Market Drivers
2.7.1. Growing Aged Population
2.7.2. Technological Advancements
2.7.3. Rise in the Healthcare Expenditure
2.7.4. Surge in Lifestyle-Oriented Diseases
2.8. Market Restraints
2.8.1. Delay in Product Launches
2.8.2. Restricting Growth Rate of A Drug Due to Generic Drugs
2.9. Market Opportunities
2.9.1. Significant Investment By Healthcare Industries in Improving Big-Data Analytical Capabilities
2.9.2. Rising Demand for Specialty Medicines
2.10. Market Challenges
2.10.1. Stringent Government Regulations
3. Drug Discovery Market Outlook - By Drug Type
3.1. Small Molecule Drug
3.2. Biologic Drug
4. Drug Discovery Market Outlook - By Technology
4.1. High Throughput Screening
4.2. Biochips
4.3. Bioinformatics
4.4. Pharmacogenomics and Pharmacogenetics
4.5. Combinatorial Chemistry
4.6. Nanotechnology
4.7. Spectroscopy
4.8. Metabolomics
4.9. Other Technologies
5. Drug Discovery Market Outlook - By Service
5.1. Drug Metabolism and Pharmacokinetics (Dmpk) Services
5.2. Chemical Services
5.3. Biological Services
5.4. Other Pharmaceutical Services
6. Drug Discovery Market Outlook - By End-User
6.1. Research Institutes
6.2. Pharmaceutical Companies
6.3. Contract Research Organizations (Cros)
6.4. Other End-Users
7. Drug Discovery Market - Regional Outlook
7.1. Latin America
7.1.1. Country Analysis
7.1.1.1. Brazil
7.1.1.2. Mexico
7.1.1.3. Rest of Latin America
8. Company Profiles
8.1. 3M Company
8.2. Abbott Laboratories Inc.
8.3. Agilent Technologies, Inc.
8.4. Antares Pharma
8.5. Astrazeneca Plc
8.6. Bayer Ag
8.7. Becton, Dickinson and Company (Bd)
8.8. Boehringer Ingelheim
8.9. Eli Lily and Company
8.10. F. Hoffmann-La Roche Ltd.
8.11. Glaxosmithkline Llc
8.12. Johnson & Johnson
8.13. Merck & Co., Inc.
8.14. Novartis
8.15. Pfizer, Inc.
8.16. Sanofi
9. Research Methodology & Scope
9.1. Research Scope & Deliverables
9.1.1. Objectives of Study
9.1.2. Scope of Study
9.2. Sources of Data
9.2.1. Primary Data Sources
9.2.2. Secondary Data Sources
9.3. Research Methodology
9.3.1. Evaluation of Proposed Market
9.3.2. Identification of Data Sources
9.3.3. Assessment of Market Determinants
9.3.4. Data Collection
9.3.5. Data Validation & Analysis
For more information about this report visit https://www.researchandmarkets.com/r/zemcac
